These vaccines induced potent antigen-specific CD8+ and CD4+ T cell responses that had antitumor activity in mice that was enhanced by combining autologous T cells modified with tumor antigens and additional adjuvant signals (Tvax) with immune checkpoint blockade (ICB) and other immunomodulators. The gene discussed is CD8A; the disease is neoplasm.